NIKKEI 225
38,165.90 -239.76 (-0.62%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.19 -0.74 (-0.90%) GOLD FUTURES
2,298.80 -4.10 (-0.18%) DOW
37,815.92 -570.17 (-1.49%) Bitcoin GBP
48,065.39 -2,654.73 (-5.23%)
CareDx, Inc (CDNA)
After hours:
| Previous close | 8.20 |
| Open | 7.87 |
| Bid | 7.71 x 200 |
| Ask | 7.79 x 300 |
| Day's range | 7.74 - 8.32 |
| 52-week range | 4.80 - 12.93 |
| Volume | |
| Avg. volume | 782,995 |
| Market cap | 401.801M |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
CareDx to Report First Quarter 2024 Financial Results
BRISBANE, Calif., April 29, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Business Wire
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 19, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 15, 2024, CareDx granted an option to purchase 700,706 shares of CareDx’s common stock (the "Inducement Option") and 487,804 restricted stock units (the "Inducement RSUs" ) to Jo
- Business Wire
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
BRISBANE, Calif., April 16, 2024--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna as its new President and Chief Executive Officer, and member of the Company’s Board of Directors, effective April 15, 2024.
